PF-06291874 is a highly potent, non-peptide and orally active Glukagon receptor antagonist. PF-06291874 is under the study for type 2 diabetes mellitus (T2DM).
In Vivo
PF-06291874 exposure is approximately dose-proportional with a half-life of ∼19.7-22.7 h. PF-06291874 has a fast on and off rate. PF-06291874 is highly bound to human plasma protein, with a mean free fraction of ∼0.55%. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
